CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

导出 OA

翻译打印收藏纠错

作者： Julia D S,Hanauer ^[1] ; Benjamin,Rengstl ^[2] ; Dina,Kleinlützum ^[3] ; Johanna,Reul ^[1] ; Anett,Pfeiffer ^[1] ; Thorsten,Friedel ^[1] ; Irene C,Schneider ^[1] ; Sebastian,Newrzela ^[1] ; Martin-Leo,Hansmann ^[2] ; Christian J,Buchholz ^[3] ; Alexander,Muik ^[2]

作者单位： Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany. ^[1] Dr. Senckenberg Institute of Pathology, Goethe-University Frankfurt, Frankfurt am Main, Germany. ^[2] Current address: BioNTech Cell and Gene Therapies GmbH, 55131 Mainz, Germany. ^[3] Current address: BioNTech RNA Pharmaceuticals GmbH, 55131 Mainz, Germany. ^[4]

关键词 CD30 VSV classical Hodgkin lymphoma retargeting virotherapy

DOI 10.18632/oncotarget.24191

PMID 29560124

发布时间 2020-03-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交